Drospi-EL (Drospirenone & Ethinylestradiol) Tablets: Verified Pharmaceutical Exporter from India | Bulk Supplier for USA, UK, Australia, Thailand, Singapore & Jamaica

Product Profile: Drospi-EL (Drospirenone & Ethinylestradiol Tablets)

Drospi-EL is an advanced combined oral contraceptive (COC) that integrates Drospirenone (a unique progestogen with anti-mineralocorticoid and anti-androgenic properties) and Ethinylestradiol (a synthetic estrogen). This formulation is widely recognized for its high contraceptive efficacy and its ability to mitigate common hormonal side effects associated with older progestogens.

1. Clinical Indications & Usage

Oral Contraception: Indicated for the prevention of pregnancy in women who choose an oral contraceptive.

Premenstrual Dysphoric Disorder (PMDD): Used for the treatment of emotional and physical symptoms of PMDD in women who choose an oral contraceptive as a method of birth control.

Moderate Acne: Indicated for the treatment of moderate acne vulgaris in women who have reached menarche, are at least 14 years of age, and wish to use an oral contraceptive for birth control.

2. Mechanism of Action

Drospi-EL utilizes a dual-action approach:

Hormonal Suppression: The estrogen and progestogen components inhibit the secretion of gonadotropins (FSH and LH), thereby suppressing ovulation and altering cervical mucus to prevent sperm migration.

Anti-mineralocorticoid Activity: Unlike other progestogens, Drospirenone mimics the effects of spironolactone. This helps counteract the estrogen-induced fluid retention, potentially reducing symptoms like bloating, breast tenderness, and weight gain.

Anti-androgenic Profile: It helps reduce the stimulation of sebaceous glands by androgens, making it effective in improving skin clarity (acne management).

3. Administration and Dosing

Regimen: Typically provided in a 21-day or 28-day cycle format. It is essential to take one tablet daily at the same time each day to maintain stable hormone levels.

Consistency: Strict adherence to the dosing schedule is required to ensure both contraceptive protection and therapeutic effect.

⚠️ Safety, Side Effects, and Monitoring

Contraindications: Do not use if the patient has a history of renal insufficiency, hepatic dysfunction, adrenal insufficiency, thromboembolic disorders, hormone-sensitive malignancies, or undiagnosed vaginal bleeding.

Smoking Warning: Smoking increases the risk of serious cardiovascular events (myocardial infarction, stroke) in women using combined oral contraceptives, especially those over 35. Smoking should be avoided.

Common Side Effects: Breakthrough bleeding, nausea, breast tenderness, mood changes, and headaches. Due to its anti-mineralocorticoid effect, potassium levels should be monitored in women taking other medications that might increase potassium (e.g., ACE inhibitors, NSAIDs).

📦 Storage, Stability & Commercial Packaging

Storage Environment: Store in a cool, dry place at room temperature (below 30°C / 86°F).

Protection: Maintain in original blister packaging to protect from moisture, heat, and UV light exposure.

Security: Keep strictly out of reach of children.

PRESCRIPTION MEDICINE IS: YES.

Disclaimer: This profile is compiled strictly for international wholesale procurement and commercial educational research. Drospi-EL is a prescription medicine and must be utilized solely under the direct guidance of a registered medical specialist. All cross-border importing setups must comply with the native health authorities of the destination country

📞 Contact Ernest Impex — Pharmaceutical Exporter from India

[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.]

🌐 Official Websites:

www.ernestimpex.com

www.oncologymedicinesupplier.com

www.ernestpharmaceuticals.com

www.ernestvision.com

📧 Corporate Email: exports@ernestpharmaceuticals.com

📦 Business Type: Exporter | Bulk Supplier | Distributor

📲 WhatsApp: +91 93599 02383

📲 WhatsApp Link: https://wa.me/919359902383